Jyothish Vijayan

So, my first question is on the pricing growth side. So, generally, we see in the diagnostics space generally a limited pricing growth. So, have you taken any price hike over the last 2 years? And what is your pricing strategy going forward considering the inflation and the competition arises?

And my second question is from the competition side. So, as of now there is some competition arising from the organized chains as well as the hospital based diagnostic lab. So are you witnessing any change in the competitive intensity across your key markets particularly in the Telangana and Karnataka?

So my question is on the operational excellence side. On the third page of your investor presentation, you mentioned that there are some key initiatives which are underway. The first one is cost optimization and the second one is driving productivity improvements. And the third one is enhancing the patient experience.

Okay. Got it. And my second question on the revenue growth side. So how much the revenue contribution -- the increased revenue contribution from the ARPOB increase or the patient product that mix increase or the volume increase. So could you please break down that?

Yes. So on the last question from my side is, in this quarter, you completed the strategy exit from Milann. So how that exit will -- you mentioned that strategy exit will sharpen the focus on core oncology and enhance the management focus and execution. So how that exit will guide or what will be the strategy? ?